The influence of roflumilast on the IV-type collagen level in patients with III stage COPD Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012
Pulmonary endothelial ACE activity may be an additional criterion for rhAPC administration in septic ALI/ARDS patients Source: Eur Respir J 2006; 28: Suppl. 50, 348s Year: 2006
Early recognition and treatment of severe sepsis and septic shock in CAP Source: Eur Respir Monogr 2014; 63: 184-204 Year: 2014
The influence of inadequate starting empirical antimicrobial therapy of septic pneumonia on outcomes at patients with angiogenic sepsis Source: Eur Respir J 2004; 24: Suppl. 48, 549s Year: 2004
C-reactive protein and the type IV collagen measurementin severe COPD: Value of roflumilast Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Changes in the vascular platelet phase of hemostasis in patients with septic and traumatic shock, presenting ARDS Source: Eur Respir J 2004; 24: Suppl. 48, 264s Year: 2004
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial Source: Eur Respir J, 52 (4) 1801220; 10.1183/13993003.01220-2018 Year: 2018
The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 85s Year: 2007
Influence of protein C activity on the PT/INR in patients receiving heparin Source: Eur Respir J 2003; 22: Suppl. 45, 221s Year: 2003
Compliance with severe sepsis bundles and its effect on outcomes of severe pneumonia and septic shock in a Chinese hospital Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
The ability of pro adrenomedullin to predict severe sepsis in patients with comunity-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011
Serum type III procollagen peptide in idiopathic pulmonary fibrosis: peptide levels and anti-fibrosis therapy Source: Eur Respir J 2005; 26: Suppl. 49, 30s Year: 2005
The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006
The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 713s Year: 2004
Effect of excluding ICU-admission on clinical outcomes in a randomized control trial studying the effect of corticosteroids in patients hospitalized with CAP Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012
The effect of diluent pH on infection rates in pulmonary hypertension patients on IV treprostinil Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010
Cardiovascular effects of high dose N-acetylcysteine in severe pneumonia-induced sepsis Source: Eur Respir J 2003; 22: Suppl. 45, 452s Year: 2003
Association of outpatient statin, ARB, and ACE inhibitor use on clinical outcomes for elderly subjects hospitalized with severe sepsis Source: Annual Congress 2013 –Interesting research questions Year: 2013
Effect of antibiotic prophylaxis on pneumonia in cardiac arrest patients treated with therapeutic hypothermia Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012